We evaluated the feasibility of T-cell-depleted haploidentical hematopoietic SCT (HHCT) in pediatric patients. Between July 2008 and January 2013, 28 patients underwent ex vivo T-cell-depleted HHCT; 9 had hematologic malignancy, 18 had nonmalignant hematologic disease, and 1 had refractory neuroblastoma. Twenty-six patients achieved neutrophil engraftment at a median of 11 days (range, 9-15 days). Two patients failed to achieve primary engraftment and five experienced graft rejection after primary engraftment. These seven patients achieved stable engraftment after a second HHCT. The cumulative incidences (CIs) of ⩾ grade II and ⩾ grade III acute GVHD were 33.3% and 14.3%, respectively, and the 1-year CI of extensive chronic GVHD was 11.1%. Four patients died of non-relapse-related causes (two of CMV disease, one of encephalopathy and one of autoimmune hemolytic anemia) and one of leukemia relapse. Non-relapse mortality at 100 days, 1 year and 2 years was 0.0%, 10.7% and 14.3%, respectively. At a median follow-up of 32.8 months (range, 17.0-72.5 months), the 2-year OS was 82.1%. OSs for nonmalignant diseases and malignant diseases were 94.4% and 60.0%, respectively (P = 0.019). Thus, HHCT is a realistic alternative for patients with malignant or nonmalignant diseases who lack a suitable donor.
INTRODUCTION
Recent advances in haploidentical hematopoietic SCT (HHCT) have improved outcomes and enabled the use of haploidentical relatives as donors for children and adults with diseases that are curable with hematopoietic cell transplantation (HCT). A recently developed transplant strategy using a CD3/CD19-depleted graft instead of CD34 + cell selection has shown improved results. [1] [2] [3] Depleting CD3 + cells is superior to selecting CD34 + cells in terms of rapid engraftment and immune reconstitution. 2, 3 Depletion of CD3 + T cells also has the advantage of increasing the number of natural killer cells, monocytes and other immunomodulating cells. 4 We recently completed our prospective study of in vitro CD3-depleted HHCT for pediatric patients lacking suitable related or unrelated donors. We reported our experience with CD3-depleted HHCT for patients with acquired SAA and patients with graft failure (GF) after allogeneic HCT. 5, 6 These patients constitute part of the current patient cohort: of 28 patients in the present cohort, 17 were included in the previous two reports. The purpose of the present study was to assess the efficacy and feasibility of CD3-depleted HHCT in the children and adolescents of our cohort with an additional 11 patients and with an extended follow-up of previously reported cases.
METHODS Patients
Between July 2008 and January 2013, 28 children and adolescents underwent a total of 35 HHCTs using in vitro CD3-depleted PBSC. All transplantation protocols were approved by the Institutional Review Board of Asan Medical Center and registered at www.clinicaltrials.gov (NCT01105273, NCT01509300 and NCT01759732). All patients and donors provided written informed consent.
Conditioning regimens and GVHD prophylaxis
All 28 patients underwent a reduced-intensity-conditioning regimen consisting of fludarabine (150-180 mg/m 2 ) and Cyclophosphamide (CY; 100-120 mg/kg). Low-dose TBI (LD-TBI; 400-600 cGy) was incorporated into the conditioning regimen in 16 patients. Most patients (24 out of 28) received additional rabbit anti-thymocyte globulin (r-ATG; 3.0-7.5 mg/kg). To prevent GVHD, calcineurin inhibitors (cyclosporine in 9 patients and tacrolimus in 19 patients) and mycophenolate mofetil were administered from the day of PBSC infusion.
Stem cell collection and graft manipulation by T-cell depletion
All donors received G-CSF for a minimum of 4 consecutive days and PBSCs were collected on days -1 and 0. CD3 + or CD3 + /CD19 + cells were depleted by negative selection using the CliniMACS system (Miltenyi-BioTec, Bergisch-Gladbach, Germany). The first five patients received grafts after depletion of only CD3 + cells, but not B cells. The remaining 23 patients received grafts after in vitro depletion of CD3 + cells and the additional depletion of CD19 + cells (5 with in vitro depletion of CD19 + cells and 18 with in vivo depletion using rituximab post transplant).
Supportive care
Patients were given antibiotics for bacterial prophylaxis, micafungin for fungal prophylaxis and acyclovir for viral prophylaxis. Since July 2011, ganciclovir (5 mg/kg twice per day) has been used for CMV prophylaxis prior to HHCT and foscarnet (60 mg/kg/day) has been used after transplantation and up until engraftment. After engraftment, valganciclovir (25 mg/kg/day) was administered until 100 days post transplantation and until the recovery of CD4 + cell numbers (4100 μL). Beginning on day 4, patients were treated with G-CSF (5 μg/kg/day) until an ANC of ⩾ 2000 μL was achieved for 3 consecutive days.
Post-transplant assessment
Viral surveillance included weekly screening for CMV using PCR and antigenemia assays and weekly screening for EBV using PCR. Preemptive therapy with ganciclovir was initiated when positive results were obtained in PCR and antigenemia assays for CMV. Acute GVHD was graded according to standard criteria and chronic GVHD was defined as absent, limited or extensive. 7, 8 Chimerism analysis
We assessed donor chimerism by using PCR-based amplification of a polymorphic STR region from unfractionated whole blood after HHCT. Since June 2011, we also performed flow cytometric analysis of lineagespecific chimerism of T, B and natural killer cells as well as a STR-PCR-based assay. Although flow cytometry has a very limited role in chimerism analysis, it can be useful for assessing chimerism status using anti-HLA Ab and distinct lineage markers in HLA-mismatched HHCT because differences in HLA Ags enable differentiation between donor and recipient cells. 9 Anti-HLA Ab was selected and cell populations were analyzed by using a BD FACSCanto II (BD Biosciences, San Jose, CA, USA) flow cytometer.
Definitions
Early GF was defined as graft loss occurring within 1 month of HHCT and included both primary GF (neutrophil counts did not exceed 500 μL at any time point) and graft rejection (GR; neutrophil counts initially exceeded 500 μL, but then decreased with complete loss of donor chimerism within 1 month of HHCT).
Statistical analysis
Cumulative incidence (CI) was used to summarize the probability of GVHD, non-relapse mortality, and CMV reactivation and disease using a competing risks model. The Kaplan-Meier method was used to calculate the probability of OS. The date of the last follow-up for all patients was 15 June 2014.
RESULTS

Patient characteristics
Of the 28 patients, 21 were male. The median age at the time of transplantation was 13.5 years (range, 1.0-21.7 years). Nine patients had hematologic malignancy (one ALL in relapse, six AML and two myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia). Of the six cases of AML, one was in CR1, two were in CR2, two were in GF after cord blood transplantations and one had hypoplastic AML not in remission. Eighteen patients had nonmalignant hematologic disease (1 Fanconi anemia, 16 acquired SAA, and 1 congenital dyserythropoietic anemia). One patient had a refractory neuroblastoma.
Graft composition
The median infused doses of CD34 + and CD3 + cells were 5.81 × 10 6 kg (range, 3.0-14.68) and 7.8 × 10 5 kg (range, 0.06-9.31), respectively ( Table 1) .
Engraftment
Of 28 patients, 26 achieved neutrophil engraftment at a median of 11 days (range, 9-15 days) after HHCT. Two patients (cases 9 and 19) failed to achieve primary engraftment and five patients (cases 7, 12, 15, 26 and 27) experienced GR after primary engraftment. All seven of these patients were heavily transfused and none received chemotherapy prior to HHCT. One patient (case 9) had a long history of SAA and moyamoya disease and the BM showed hypoplastic AML at the time of referral. This patient proceeded to HHCT without chemotherapy while not in remission. All seven patients, including the two with primary GF, received a second HHCT and achieved stable engraftment (Table 1) .
Engraftment kinetics
Since June 2011, we checked lineage-specific chimerism using flow cytometry based on the disparity in HLA Ags between donor and recipient. HLA differences allowed donor and recipient cells to be distinguished in 12 of 16 patients who received HHCT between June 2011 and January 2013. Natural killer cells were the first lymphocyte subset detectable after HHCT, comprising 440% of lymphocytes at +10 days. Although T-cell recovery was delayed, T-cell chimerism was an early predictor of GF. The mean percentage of donor T cells at day 10 post transplantation in patients who experienced GF was significantly lower than that in patients who achieved sustained engraftment (16.0% (range, 0-56.7%) versus 86.9% (range, 53.2-100%), P = 0.005; Figure 1 ).
Acute and chronic GVHD Twenty-one patients, excluding seven patients who experienced early GF, were evaluated for acute GVHD. Four patients developed grade II and three developed grade III acute GVHD at a median of 15 days (range, 7-78). No patients had grade IV acute GVHD. All seven patients were successfully treated with steroids and calcineurin inhibitors. The CIs of ⩾ grade II and ⩾ grade III acute GVHD were 33.3% and 14.3%, respectively (Figure 2 ). Clinically extensive chronic GVHD developed in three patients, giving an estimated 1-year probability of 11.1%. One of these three patients remains on tacrolimus and steroids with long-term taper and showed good control of GVHD. The remaining two patients (cases 14 and 17) have no active chronic GVHD and are not taking immunosuppressants at the time of this report. There were no GVHD-related deaths at last follow-up. Abbreviations: ATG = rabbit anti-thymocyte globulin; CY = cyclophosphamide; FLU = fludarabine; TCD = T-cell depletion; HHCT = haploidentical stem cell transplantation.
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Chimerism data
Mixed chimerism using STR-PCR with unfractionated whole blood was detected in two patients: one had SAA (81-97% donor cells) and the other had Fanconi anemia (80-93% donor cells). The remaining 26 patients showed complete donor chimerism.
Immune reconstitution and infections
The immune reconstitution of all 28 patients who had sustained stable engraftment was examined, including that of the seven patients who received a successful salvage transplant ( Figure 3 ). The median number of CD4 + cells reached~100 cells/μL at 3 months after transplant. The major cause of infection was CMV reactivation, which occurred in 15 of the 28 patients at a median of 47 days after their first HHCT, showing a CI of 53.6%. Four patients developed CMV diseases (retinitis in two, pneumonia in one and encephalitis in one), and two patients died of CMV disease (pneumonia and encephalitis in one patient each). After July 2011, when CMV prophylaxis with ganciclovir and foscarnet was initiated, only 5 out of the 15 patients experienced transient reactivation and none developed CMV disease. The CI of CMV infection was significantly lower with prophylaxis than without prophylaxis. EBV reactivation occurred in 11 patients at a median of 75 days post transplantation. One patient (case 3) developed post-transplant lymphoproliferative disorder at +68 days and was successfully treated with rituximab and chemotherapy. One patient (case 26) developed invasive fungal infection at +67 days, which was successfully treated with voriconazole. No other cases of serious bacterial or fungal infections occurred during the study period. Table 2 shows a summary of protocol modifications and posttransplant events of the enrolled patients. In the initial analysis of nine cases (cases 1-9), two patients developed GF, for which LD-TBI was added to the conditioning regimen. At the second interim analysis of 15 patients (cases 1-15), four patients experienced GF. Three of them received a lower dose of CD3 + cells at o 2 × 10 5 kg. Given the higher incidence of GF in patients receiving grafts containing lower levels of CD3 + cells, we fixed the infused CD3
Protocol modification
+ cell dose at 1-6 × 10 6 kg in an attempt to decrease the GF rate (cases [16] [17] [18] [19] [20] [21] . At the third interim analysis of 21 patients (cases 1-21), severe acute GVHD ⩾ 3 occurred in two patients and extensive chronic GVHD occurred in two patients. All three patients received a higher dose of CD3 + cells at 42 × 10 6 kg. Thereafter, the dose of CD3 + cells was reduced to~7 × 10 5 kg in the fourth study period.
Mortality and survival
Of 28 patients, 1 patient died of relapse at +460 days and 4 patients died of causes other than relapse. Two of these four patients died of CMV infections at +103 and +228 days, respectively, and one patient died of encephalopathy related to moyamoya disease at +301 days. The remaining one patient died of severe autoimmune hemolytic anemia with pure red-cell aplasia after booster infusion of CD34 + cells at +457 days. The CIs of non-relapse mortality at 100 days, 1 year and 2 years were 0.0%, 10.7% and 14.3%, respectively. At a median follow-up of 32.8 months (range, 17.0-72.5 months), the 2-year OS was 82.1%. The OSs for nonmalignant diseases and malignant diseases were 94.4% and 60.0%, respectively (P = 0.019) (Figure 4 ).
DISCUSSION
Our study demonstrates that HHCT using ex vivo T-cell-depleted grafts is a feasible treatment modality with a favorable outcome in children and adolescents with malignant or nonmalignant diseases. There have been several reports on HHCT using CD3-depleted grafts in pediatric patients.
2,10-14 The Tübingen group reported their experience with CD3/19-depleted HHCT using reduced-intensity conditioning in 38 pediatric patients. 2 The authors reported a primary engraftment rate of 83%, with GR occurring in 17% of patients. Severe acute GVHD ⩾ III developed in 3% of the patients and only one patient died of a non-relapse cause, leading to a TRM of 2.6%. The EFS was 70% for patients with nonmalignant diseases and patients in remission at the time of transplant, whereas it was~20% for patients with chemorefractory disease pre-transplant. 10 Recently, Lang et al. 15 reported the results of CD13/19-depleted HHCT for 46 pediatric patients with leukemia. In that study, the TRM was low (8% at 1 year) and the EFS was favorable (46%) for patients who received a first HHCT in CR1-3. In our study, TRM at 1 year was 10.7% and OS for 25 patients with nonmalignant diseases and those with malignant diseases in remission at the time of transplantation was 92.0%. Moreover, the survival of all enrolled patients was 82.1%, which is largely comparable to that reported for HCT from HLA-matchedrelated or unrelated donors. In addition, Leung et al. 16 reported a similar outcome of HCT regardless of donor source in children with very high-risk leukemia.
In our study, GF was the major event, particularly GF occurring within 1 month post transplantation. GF is a life-threatening complication after allogeneic HCT and is associated with multiple factors, including depletion of T cells, HLA disparity between donor and recipient, the conditioning regimen and stem cell source. [17] [18] [19] [20] [21] GF after HHCT using T-cell-depleted grafts occurs in 5-20% of patients. 2, 22, 23 In addition, GF is more common in cases of nonmalignant disease, including SAA, especially heavily transfused cases, than in acute leukemia. [24] [25] [26] In our cohort, seven patients experienced early GF within 1 month post HHCT. Of 16 patients with SAA, 5 experienced early GF. All seven patients received a large number of transfusions before transplantation. Abbreviations: AIHA = autoimmune hemolytic anemia; CDA = congenital dyserythropoietic anemia; CR = complte remission; E = extensive; EGF = early graft failure; FA = Fanconi anemia; GF = graft failure; GR = graft rejection; LD-TBI = low-dose TBI; MDS = myelodysplastic syndrome; NBL = neuroblastoma; NE = nonengraftrment; RCMD = refractory cytopenia with multilineage dysplasia.
Notably, no patients received chemotherapy prior to HHCT. In this study, the high incidence of GF was the major issue in patients with BM failure. Although several studies reported the use of cord blood transplantation for acquired SAA, a major problem was high GF rates, with a CI of neutrophil recovery of 51-55% in large multicenter trials. 27, 28 In addition, the survival rates in those studies were disappointing. Moreover, the outcome of HCT using mismatched unrelated transplants in patients with acquired aplastic anemia was not encouraging. 29 Although GF also occurred in a significant proportion of our current study patients who received many transfusions prior to the transplant, all of our patients with GF were successfully rescued by the second transplantation, and moreover, the OS rate in our series was promising. Our study findings strongly suggest that HHCT could be offered as a possible alternative to patients with SAA who lack a matched-related or unrelated donor, although further improvements that reduce GF after HHCT are warranted. A recent report on CD3-depleted HHCT for 46 patients with pediatric leukemia, including advanced MDS, showed that six had primary GF and an additional six had GR. 15 In our study, only one patient with AML, which had evolved from long-standing SAA, experienced early GF.
GVHD is another barrier in HHCT. The Tübingen group reported CIs of 44% and 8% for acute GVHD grade II-IV and grade III-IV, respectively, in CD3-depleted HHCT. 2 In addition, the CI of chronic GVHD was 28% in that study. In our study, the CIs of acute GVHD II-IV and III were 33.3% and 14.3%, respectively, and no patients had grade IV GVHD. Three patients developed extensive chronic GVHD. Notably, all three patients received TBI-containing conditioning along with a higher number of T cells, ⩾ 25 × 10 5 kg, than the median of 7.8 × 10
5 T cells/kg in this cohort. Both TBI and high T-cell doses may be related to the development of extensive chronic GVHD.
In our present study, the number of T cells infused into patients was~1-log higher, at a median of 7.8 × 10 5 kg, than that of previous reports, which ranged between 0.49 × 10 5 kg and 1.4 × 10 5 kg. [10] [11] [12] [13] [14] Although all of our patients received GVHD prophylaxis with calcineurin inhibitors and mycophenolate mofetil, the incidences of severe acute and chronic GVHD were acceptable for our partial depletion of T cells.
The protocol was revised several times during the periods of this study (Table 2) . Major post-transplant events according to the study period are summarized in Table 3 . In an attempt to decrease the GF rate, LD-TBI was added to the conditioning regimen and a higher dose of T cells was infused into patients by add-back from the raw bag. In the third study period, a higher dose of T cells, over 1 × 10 6 kg, seemed to be associated with a higher incidence of severe acute GVHD and extensive chronic GVHD. A lower dose of T cells of around 7 × 10 5 kg in the fourth study period reduced the incidence of severe GVHD. Although two patients experienced early GF out of the seven patients in the fourth period, six of these seven patients had a nonmalignant disease with a history of multiple transfusions prior to transplantation. At the present time, we cannot draw any firm conclusions from this small number of patients with heterogeneous disease regarding the beneficial effect of LD-TBI as a conditioning regimen and a higher dose of T cells on preventing early GF. Our future trial will include LD-TBI and fix the dose of T cells at 5 × 10 5 kg to elucidate their role in preventing GF and improving transplant outcomes.
One of the relevant findings of our current study was the association between the lineage-specific chimerism of T cells in the early post-transplant period and graft fate. We performed flow cytometric analysis of lineage-specific chimerism for T, B and natural killer cells to observe the pattern of hematopoietic regeneration after HHCT. T-cell chimerism at +10 days was a significant indicator of impending GF after HHCT. Given the high Abbreviations: aGVHD = acute GVHD; cGVHD = chronic GVHD; GF = graft failure; NM = nonmalignant.
rate of GF in patients with o 50% donor chimerism at +10 days, any interventions, including DLI, could be considered at this level of chimerism in the early post-transplant period. Delayed immune reconstitution and subsequent infections are another major limitation in HHCT. [30] [31] [32] CMV was the most prevalent infectious agent in our present investigation with two patients in our cohort dying of CMV disease. In July 2011, we initiated CMV prophylaxis with ganciclovir and foscarnet for all patients, which led to a decreased incidence of CMV reactivation and no development of CMV disease. Therefore, CMV prophylaxis with the same drugs will be included in our future trial.
Although our current study was limited by a small number of patients, heterogeneous disease and some protocol modifications, we here provide along with the previous trials, further evidence of successful HHCT. We recently changed the depletion method from CD3 + cells to TCRαβ + cells in an attempt to decrease GF in nonmalignant disease and to decrease relapse in advanced malignant disease. In our institute, a HHCT protocol using a TCRαβ-depleted graft along with TBI-containing conditioning and a fixed dose of TCRαβ + cells is ongoing in an effort to improve the outcomes of pediatric patients with malignant and nonmalignant disease.
In the current study, outcomes of HHCT using CD3-depleted grafts were found to be quite favorable with a low non-relapse mortality and high survival rate. These results will become a basis for a comparison with the results of a future study in our laboratory using TCRαβ-depleted grafts.
